Connection

Richard Drake to Prostatic Neoplasms

Back to Details
This is a "connection" page, showing publications Richard Drake has written about Prostatic Neoplasms.
Richard Drake
Connection Strength
4.135
Prostatic Neoplasms
  1. Zonal regulation of collagen-type proteins and posttranslational modifications in prostatic benign and cancer tissues by imaging mass spectrometry. Prostate. 2020 09; 80(13):1071-1086.
    View in: PubMed
    Score: 0.447
  2. How else can we approach prostate cancer biomarker discovery? Expert Rev Mol Diagn. 2020 02; 20(2):123-125.
    View in: PubMed
    Score: 0.421
  3. Altered glycosylation in prostate cancer. Adv Cancer Res. 2015; 126:345-82.
    View in: PubMed
    Score: 0.306
  4. MALDI imaging mass spectrometry profiling of N-glycans in formalin-fixed paraffin embedded clinical tissue blocks and tissue microarrays. PLoS One. 2014; 9(9):e106255.
    View in: PubMed
    Score: 0.297
  5. The proteomics of prostate cancer exosomes. Expert Rev Proteomics. 2014 Apr; 11(2):167-77.
    View in: PubMed
    Score: 0.287
  6. Increased bisecting N-acetylglucosamine and decreased branched chain glycans of N-linked glycoproteins in expressed prostatic secretions associated with prostate cancer progression. Proteomics Clin Appl. 2013 Oct; 7(9-10):677-89.
    View in: PubMed
    Score: 0.278
  7. In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine. Proteomics. 2013 May; 13(10-11):1667-1671.
    View in: PubMed
    Score: 0.270
  8. In-depth proteomic analyses of direct expressed prostatic secretions. J Proteome Res. 2010 May 07; 9(5):2109-16.
    View in: PubMed
    Score: 0.220
  9. Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. J Proteome Res. 2009 Feb; 8(2):620-30.
    View in: PubMed
    Score: 0.202
  10. Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. J Proteomics. 2009 Aug 20; 72(6):907-17.
    View in: PubMed
    Score: 0.201
  11. Racial Differences in Patient Portal Activation and Research Enrollment Among Patients With Prostate Cancer. JCO Clin Cancer Inform. 2021 06; 5:768-774.
    View in: PubMed
    Score: 0.119
  12. Financial toxicity and strain among men receiving prostate cancer care in an equal access healthcare system. Cancer Med. 2020 12; 9(23):8765-8771.
    View in: PubMed
    Score: 0.114
  13. Social and clinical determinants of physical activity in prostate cancer survivors. Support Care Cancer. 2021 Jan; 29(1):459-465.
    View in: PubMed
    Score: 0.110
  14. Co-morbidities in a Retrospective Cohort of Prostate Cancer Patients. Ethn Dis. 2020; 30(Suppl 1):185-192.
    View in: PubMed
    Score: 0.109
  15. Characterization and Evidence of the miR-888 Cluster as a Novel Cancer Network in Prostate. Mol Cancer Res. 2018 04; 16(4):669-681.
    View in: PubMed
    Score: 0.094
  16. Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer. Nat Commun. 2016 06 28; 7:11906.
    View in: PubMed
    Score: 0.084
  17. Dysregulated expression of cell surface glycoprotein CDCP1 in prostate cancer. Oncotarget. 2015 Dec 22; 6(41):43743-58.
    View in: PubMed
    Score: 0.081
  18. miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration. Cell Cycle. 2014; 13(2):227-39.
    View in: PubMed
    Score: 0.070
  19. Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. J Clin Invest. 2013 Oct; 123(10):4344-58.
    View in: PubMed
    Score: 0.069
  20. Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol Cell Proteomics. 2012 Dec; 11(12):1870-84.
    View in: PubMed
    Score: 0.065
  21. MALDI tissue imaging: from biomarker discovery to clinical applications. Anal Bioanal Chem. 2011 Jul; 401(1):17-27.
    View in: PubMed
    Score: 0.059
  22. Targeted identification of metastasis-associated cell-surface sialoglycoproteins in prostate cancer. Mol Cell Proteomics. 2011 Jun; 10(6):M110.007294.
    View in: PubMed
    Score: 0.059
  23. Molecular pathology of prostate cancer. Cancer Biomark. 2010; 9(1-6):441-59.
    View in: PubMed
    Score: 0.054
  24. Proteomic expression profiling and identification of serum proteins using immobilized trypsin beads with MALDI-TOF/TOF. J Proteome Res. 2009 Sep; 8(9):4182-92.
    View in: PubMed
    Score: 0.052
  25. Imaging mass spectrometry of a specific fragment of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 2 discriminates cancer from uninvolved prostate tissue. Clin Cancer Res. 2009 Sep 01; 15(17):5541-51.
    View in: PubMed
    Score: 0.052
  26. Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine. J Proteome Res. 2012 Apr 06; 11(4):2386-96.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.